doi: 10.1136/bmj.h1377.
Avastin and Lucentis: a guide through the legal maze
- PMID: 25834023
- DOI: 10.1136/bmj.h1377
Item in Clipboard
Avastin and Lucentis: a guide through the legal maze
BMJ.
.
No abstract available
Similar articles
-
Why have UK doctors been deterred from prescribing Avastin?BMJ. 2015 Apr 1;350:h1654. doi: 10.1136/bmj.h1654. BMJ. 2015. PMID: 25834024 No abstract available.
-
Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.BMJ. 2013 Jul 23;347:f4678. doi: 10.1136/bmj.f4678. BMJ. 2013. PMID: 23881948 No abstract available.
-
A licence to cure.BMJ. 2015 Apr 1;350:h1723. doi: 10.1136/bmj.h1723. BMJ. 2015. PMID: 25834026 No abstract available.
-
Off-label use of bevacizumab for wet age-related macular degeneration in Europe.Graefes Arch Clin Exp Ophthalmol. 2020 Mar;258(3):503-511. doi: 10.1007/s00417-019-04569-8. Epub 2019 Dec 30. Graefes Arch Clin Exp Ophthalmol. 2020. PMID: 31889214 Review.
-
Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.Prescrire Int. 2015 Sep;24(163):201-4. Prescrire Int. 2015. PMID: 26417625 Review.
Cited by
-
Licence to save: a UK survey of anti-VEGF use for the eye in 2015.Eye (Lond). 2016 Nov;30(11):1404-1406. doi: 10.1038/eye.2016.154. Epub 2016 Aug 12. Eye (Lond). 2016. PMID: 27518544 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
